ONCY — ONCOLYTICS BIOTECH INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1129928 ·
Last close
$0.84
Market Cap
$107.63M
52W High
$1.18
52W Low
$0.73
ADV30
917,852
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -9,281,000 | -9,243,000 | 8,161,000 | 5,493,000 | 13,291,000 |
| Dec 2025 | 0 | — | -9,651,891 | -9,177,897 | 7,582,000 | 5,202,000 | 11,381,000 |
| Sep 2025 | 0 | — | -9,944,315 | -10,346,686 | 10,818,753 | 8,875,157 | 10,736,124 |
| Jun 2025 | 0 | — | -4,169,986 | -4,505,426 | 14,597,143 | 10,688,786 | 10,147,258 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-22,672,000
Investing CF
$-11,000
Financing CF
$17,551,000
CapEx
$-13,970
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.29
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-438,738,000
Inventory
—
Receivables
$961,000
ST Investments
—
EBIT TTM
$-33,047,191
Pretax Income TTM
$-33,192,965
Interest Exp TTM
—
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -28,725,000 | -28,759,000 | 7,582,000 | 11,381,000 | — | -20,112,000 |
| Dec 2024 | 0 | -25,542,000 | -22,794,000 | 13,421,000 | 10,123,000 | — | -19,883,000 |
| Dec 2023 | 0 | -25,471,883 | -20,919,644 | 29,262,777 | 8,485,602 | — | -21,444,294 |
| Dec 2022 | 0 | -19,837,902 | -18,298,703 | 27,508,105 | 7,981,138 | — | -17,208,223 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.24
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| QUCY | Quantum Cyber N.V. | $110.13M | $1.31 | — |
| RFL | Rafael Holdings, Inc. | $112.16M | $2.19 | — |
| RANI | Rani Therapeutics Holdings, Inc. | $101.46M | $0.88 | — |
| BMEA | Biomea Fusion, Inc. | $115.25M | $1.59 | — |
| COYA | Coya Therapeutics, Inc. | $116.35M | $4.96 | — |
News headlines (Yahoo Finance, 1h cache)
Why Oncolytics Biotech Just Cleared A Hurdle That Stalls Most Cancer Trials
2026-08-19 06:15 · Yahoo
Oncolytics Biotech Shares Climb Ahead of Planned FDA Meeting on REO 033 Trial (ONCY)
2026-07-13 14:13 · Yahoo
ONCY Stock Surged Today – Here’s What Securing A Key Immunotherapy Patent Means For Oncolytics
2026-06-16 16:42 · Yahoo
Oncolytics Biotech (ONCY) Valuation Check As New Pelareorep RAS Combo Data Draws Investor Attention
2026-06-04 06:11 · Yahoo
From Ambrx to Oncolytics: Why Jared Kelly Believes the Market May Be Missing the Bigger Oncology Story
2026-05-26 13:00 · Yahoo
Oncolytics Biotech Reports Data in Colorectal Cancer Study
2026-05-06 22:48 · Yahoo
CEO Chat with Jared Kelly, CEO of Oncolytics Biotech
2026-05-01 10:48 · Yahoo
ONCY: Seeking Registration Pathway for Part B of REO 033 Trial
2026-07-16 11:16 · Yahoo
ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment Study
2026-06-01 15:26 · Yahoo
ONCY: Aligns with FDA on Pivotal Trial for Pelareorep in Anal Cancer
2026-05-19 11:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.